EQT AB has agreed to acquire Qiagen NV for around €9.6 billion ($10.8 billion), bringing an end to years of takeover speculation involving the European molecular testing company.
EQT AB has agreed to acquire Qiagen NV for around €9.6 billion ($10.8 billion), bringing an end to years of takeover speculation involving the European molecular testing company.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)